Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays is a research paper published in Acta Pharmaceutica Sinica B (2021). On theSindex it has a DataRank of 0. It has been cited 86 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Allergy and Infectious Diseases
Grant: AI147325
National Institute of Allergy and Infectious Diseases
Grant: AI157046
National Institute of Allergy and Infectious Diseases
Grant: AI158775
NIAID NIH HHS
Grant: R01 AI158775
NIAID NIH HHS
Grant: R01 AI147325
NIAID NIH HHS
Grant: R01 AI157046
National Institutes of Health
Grant: 5R01AI158775-03
Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals
National Institutes of Health
Grant: 7R01AI157046-03
Drug target validation of the enterovirus D68 2A protease
National Institutes of Health
Grant: 7R01AI147325-04
High Throughput Screening of Inhibitors Targeting the Enterovirus A71 and D68 2A proteases
University of Pennsylvania
FWCI
4.45
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals